• About Us
      • Mission
      • Members
      • Board of Directors
      • Staff
      • Annual Meeting
    • Economic Impact
    • Issues
      • PAMA
      • Economic Impact of Clinical Labs
      • Protecting Access to Medicare Act
      • Laboratory Developed Tests
      • Reimbursement and Coverage
      • Patient Access to Lab Services
      • Value of Labs
      • IOAS Exception and Self-Referral
      • Regulatory Issues
      • Value of Health IT Data Standards
      • TRICARE Non-Coverage of LDTs
    • Take Action
    • News
      • ACLA Blog
      • ACLA Press Releases
      • Comments and Letters
      • ACLA In The News
    • Resources
      • CPT Committee
      • NGS NCD Work Group
      • Prior Authorization Work Group
    • Join Us
    • Home
    • Contact Us
    • ACLA 2020 Annual Meeting
ACLA
    • Home
    • Contact Us
    • ACLA 2020 Annual Meeting
  • About Us
    • Mission
    • Members
    • Board of Directors
    • Staff
    • Annual Meeting
  • Economic Impact
  • Issues
    • PAMA
    • Economic Impact of Clinical Labs
    • Protecting Access to Medicare Act
    • Laboratory Developed Tests
    • Reimbursement and Coverage
    • Patient Access to Lab Services
    • Value of Labs
    • IOAS Exception and Self-Referral
    • Regulatory Issues
    • Value of Health IT Data Standards
    • TRICARE Non-Coverage of LDTs
  • Take Action
  • News
    • ACLA Blog
    • ACLA Press Releases
    • Comments and Letters
    • ACLA In The News
  • Resources
    • CPT Committee
    • NGS NCD Work Group
    • Prior Authorization Work Group
  • Join Us

ACLA Blog

During emergencies and in everyday life, labs support public health goals

June 05, 2019 Categories: ACLA Blog, Featured News, Value of Labs

Clinical laboratory diagnostics advance public health goals in communities across the country every single day. For patients facing diabetes, heart disease, liver disease, kidney disease, prostate and colon cancers, anemia, infections and countless other common health conditions, routine lab tests are often the starting point for monitoring, diagnosing and treating disease.

But our role in public health doesn’t stop there. Commercial labs have a long history of supporting public health needs during emergencies. This is a role we take seriously because when an outbreak occurs, clinical laboratories are at the forefront of emergency responses.

Most recently, the Zika virus outbreak in 2016 demonstrated the essential role commercial labs play during public health emergencies. More than 5,000 symptomatic cases of Zika virus were reported in the continental U.S. in 2016. During the outbreak, the Centers for Disease Control (CDC) released new guidelines for providers caring for pregnant women with possible Zika exposure, recommending that all pregnant women in the United States and U.S. territories be assessed for possible exposure at each prenatal care visit. As the demand for testing quickly grew beyond the capacity of state public health labs, CDC engaged commercial labs to meet the rising public need.

As public and private sector partners reflected on the response to the Zika outbreak, stakeholders identified the need for greater collaboration to prepare for future public health emergencies. In response, CDC and ACLA, along with the Association of Public Health Laboratories (APHL) and the Council of State and Territorial Epidemiologists (CSTE), established a memorandum of understanding (MOU) to strengthen coordination between private industry and public health agencies, establish clear lines of communication, and clarify and streamline regulatory processes for diagnostic testing in emergencies.

Building on this development, ACLA and several of our members were proud to participate in CDC’s tabletop exercise last month to strengthen communications and diagnostic laboratory surge capacity among public and private sector partners during a public health emergency. The exercise simulated a real-life infectious disease outbreak, requiring participating organizations to put their rapid response plans to the test and identify gaps and potential solutions to guide future preparedness efforts.

The exercise also provided an important opportunity to reflect on the ways in which clinical labs support public health goals. From developing cutting-edge tests to help diagnose a patient in the early stages of disease, to responding to epidemics in coordination with our public health partners, clinical labs continue to lead groundbreaking diagnostic efforts, promoting patient access to lifesaving tests when they need it most.

Print page / Save as PDF

News

  • Press Releases
  • Letters and Comments
  • ACLA in the News

Issues

  • Economic Impact of Clinical Labs
  • Protecting Access to Medicare Act
  • Laboratory Developed Tests
  • Reimbursement and Coverage
  • Patient Access to Lab Services
  • Value of Labs
  • Regulatory Issues
  • Value of Health IT Data Standards
  • TRICARE Non-Coverage of LDTs

Fact Sheets

  • Value of Labs
  • Threats to Lab Services
  • Impacts of HHS’ Cuts to Lab Services

Media Contact

Grace Montgomery
Phone: (202) 499 2050
Email: press@acla.com

Back To Top

menu1

  • Economic Impact of Clinical Labs
  • Value of Lab Testing
  • Take Action
  • Join Us
  • Members
  • Contact Us

About Us

  • Mission
  • Members
  • Board of Directors
  • Staff
  • Annual Meeting

Issues

  • Economic Impact of Clinical Labs
  • Protecting Access to Medicare Act
  • Laboratory Developed Tests
  • Reimbursement and Coverage
  • Patient Access to Lab Services
  • Value of Labs
  • Regulatory Issues
  • Value of Health IT Data Standards
  • TRICARE Non-Coverage of LDTs

News

  • ACLA In The News
  • ACLA News
  • ACLA Press Releases
  • Comments and Letters
  • ACLA Blog

Address

202-637-9466
American Clinical Laboratory Association
1100 New York Ave, NW, Suite 725 West
Washington, DC 20005 USA
ACLA